$SNBP: Potential for Pharma Profits
January 18th, 2010 at 10:03 am Posted by
If you’ve been following The Dean on Twitter, you’d know that The Dean’s Honors Class learned that $SNBP is The Dean’s next promoted stock pick.
Sinobiopharma, Inc. (OTC: SNBP.OB) is an innovative biotechnology company engaged in the research and development, manufacture and marketing of biopharmaceutical products in the world’s fastest growing pharmaceutical market—China.
The Dean’s excited about $SNBP‘s profit potential, especially because the company recently announced strong quarterly earnings. Based on these figures, $SNBP increased revenues by more than $2 million and is setting the stage for growth and more positive figures in the year ahead.
What does that mean? The Dean believes $SNBP is extremely undervalued with a market cap of less than $30 million.
In fact, exactly two months ago, Zacks Equity Research initiated investment research on $SNBP with a six month target price of $0.80. Since $SNBP closed at $0.315 Friday, that could mean a potential gain of 154% in the next few months.
The Dean has taught all of his students that China has seen unprecedented growth and, according to the Southern Medicine Economic Research Institute (SMERI), China’s pharmaceutical market is set to grow 23% year-on-year in 2010, with more than $29 billion being added to the country’s drug market.
Where does $SNBP fit in? With production rights to 23 drugs on China’s National Essential Drug List, The Dean likes $SNBP‘s potential for pharma profits.
